GLP-1 medications are prescription drugs originally developed for diabetes that are now also used in weight management
The combination according to the invention, in any form, may be suitable for administration to human subjects, the preferred administration route being oral administration
The LEAD (Liraglutide Effect and Action Diabetes) program reported that liraglutide significantly reduced weight and improved glycated haemoglobin (HbA1c) compared to placebo/standard of care [24,25,26,27,28,29,30,31]
GLP-1 drugs were originally developed to treat diabetes and obesity
Setria is manufactured by Kyowa Hakko and is the glutathione form used in the landmark Richie et al
Jason Emer told Fox News Digital that a number of variables could be fueling the slender fad that has been sweeping the industry